Clopidogrel Tablet
Product Images NDC 50090-7467

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-7467). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clop02-a (Clop02 A)

This text describes the co-administration of different proton pump inhibitors (PPIs) and their effects on the active metabolite AUC (Area Under the Curve) of Plavix. The listed PPIs are Dexlansoprazole at 60 mg, Lansoprazole at 30 mg, Pantoprazole at 80 mg, and Omeprazole at 50 mg. The text includes information on the mean and 90% confidence interval of the effects on the active metabolite AUC when these PPIs are co-administered. This data can be used to analyze the relative change in the effects of Plavix when administered with these PPIs compared to Plavix administered alone.*

FDA Label Image

Clop03-a (Clop03 A)

This text provides a comparison of cumulative event rates (%) related to cardiovascular death, myocardial infarction, and stroke between placebo (+ aspirin) and clopidogrel (+ aspirin) over a period of 12 months of follow-up. The results show a statistically significant difference with a p-value of 0.00009. "Other standard therapies were used as appropriate."*

FDA Label Image

Clop04-a (Clop04 A)

This text provides a summary of patient information and treatment received in a study comparing Clopidogrel and Placebo. It includes data on previous medical conditions like MI and Stroke, as well as the administration of medications such as Heparin/LMWH, Aspirin, GPIIb/la Antag, Beta-Blocker, and Ace Inhibitor. The table also lists the number and percentage of patients receiving Clopidogrel or Placebo and their respective outcomes. Additionally, it shows the Hazard Ratio with its corresponding confidence interval (95% CI) for the treatment comparison.*

FDA Label Image

Clop08-a (Clop08 A)

This text provides information on the cumulative event rate (%) of fatal or non-fatal vascular events observed with aspirin and clopidogrel over a period of 30 months of follow-up. The data suggests a statistical significance at a p-value of 0.045.*

FDA Label Image

Clop_01 (Clop 01)

FDA Label Image

Clop_05 (Clop 05)

This text provides data on the number of deaths and risk reduction in a study comparing a placebo group to a group taking Clopidogrel Tablets. It shows that there were 1845 deaths (8.1%) in the placebo group and 1726 deaths (7.5%) in the Clopidogrel Tablets group, resulting in a 7% proportional risk reduction with a significance level of p = 0.03. The study also mentions that all treated patients received aspirin.*

FDA Label Image

Clop_06 (Clop 06)

This text involves a comparison between a placebo and Clopidrogel Tablets in terms of event occurrence related to death, reinfarction or stroke before discharge. The study found a 9% proportional risk reduction with Clopidrogel Tablets compared to the placebo. The data is tracked up to 28 days post-randomization, with all treated patients also receiving aspirin.*

FDA Label Image

Clop_07 (Clop 07)

This appears to be a data table showing different subgroups based on factors like gender, age, hours since onset, blood pressure, heart rate, and whether fibrinolytic agents were given. It also includes information on the administration of Clopidogrel and Placebo, with the percentage breakdown for each category. Odds Ratio with a 99% confidence interval is also mentioned in the text.*

FDA Label Image

Clop_09 (Clop 09)

This is a description of the results showing the respective percentages of patients taking Clopidogrel tablets and Aspirin in different conditions such as stroke and PAD. The data also includes the number of participants and the hazard ratio with a 95% confidence interval.*

FDA Label Image

Label Image (Lbl500907467)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.